Prot# PDX-012: A Randomized, Phase 2b, Multi-Center Study of Pralatrexate Versus Erlotinib in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-Based Treatment